307280 — Wonbiogen Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩65bn
- KR₩64bn
- KR₩30bn
- 84
- 46
- 68
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 37.2 | -104 | -660 | 3,272 | 5,961 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -86 | -73.4 | 3,379 | 2,370 | 1,602 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.17 | 174 | -1,216 | -1,054 | -4,291 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -46.6 | -3.38 | 2,384 | 5,782 | 4,835 |
Capital Expenditures | — | — | -2,338 | -6,568 | -1,735 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | -174 | -143 | 717 | -854 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | -174 | -2,481 | -5,852 | -2,589 |
Financing Cash Flow Items | — | — | -164 | -1,000 | -1.32 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 0 | 6,571 | -4,300 | -2,429 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -46.6 | -177 | 6,476 | -4,445 | -190 |